SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Hypnose eye with sharp lines. Focus illusion.
Autoimmune disease
Argenyx’s Vyvgart Flops Phase III Thyroid Eye Disease Test, Raising Risk for Ongoing Trials
Vyvgart, an FcRn inhibitor already approved for generalized myasthenia gravis, is also being tested in myositis, Sjögren’s disease and the “clinically related” Graves disease.
December 15, 2025
 · 
1 min read
 · 
Annalee Armstrong
Illustration showing hurdles along a path ending in an arrow
Multiple sclerosis
Sanofi’s MS Drug Fails Phase III Trial, While FDA Again Delays Approval Application
Sanofi’s multiple sclerosis hopeful tolebrutinib faced dual setbacks on Monday, with a late-stage failure in one form of the disease and yet another regulatory setback in another.
December 15, 2025
 · 
2 min read
 · 
Annalee Armstrong
Man jumping, running, and winner holding trophy. Competition, challenge, risk and reward concept. Vector illustration.
Approvals
Milestone’s Long Regulatory Road Ends in Approval for Cardamyst
The FDA had previously turned back the heart rhythm nasal spray twice, once in late 2023 with a refusal to file letter and again in March this year, when it flagged manufacturing issues.
December 15, 2025
 · 
2 min read
 · 
Tristan Manalac
Rheumatoid arthritis (RA) commonly causes inflammation in the hands, leading to pain, swelling, and stiffness in the joints, particularly the small joints of the fingers and wrists. This inflammation results from the immune system attacking the body's own joint tissues, causing the synovium (lining of the joint) to become inflamed and release chemicals that damage nearby tissues.
Mergers & acquisitions
Sobi Makes $1.5B Gout Play With Arthrosi Acquisition
For $950 million upfront, Sobi will gain ownership to pozdeutinurad, an oral URAT1 inhibitor that performed well in Phase II studies.
December 15, 2025
 · 
2 min read
 · 
Tristan Manalac
COVID-19
Prasad’s Claim of 10 Pediatric Deaths From COVID-19 Shots Overblown: Report
The FDA’s Vinay Prasad recently claimed in an internal memo that at least 10 children have died from coronavirus vaccines, but an internal safety review showed that the count was much lower.
December 15, 2025
 · 
2 min read
 · 
Tristan Manalac
Sponsored
Disruptive Innovation in Cancer Research: The New Era of Oncology
As clinical research evolves, disruptive trial designs are reshaping how oncology advances. By integrating novel methodologies, strategic innovation, and patient-centered approaches, MEDSIR is driving a new era in cancer research, one that accelerates development, enhances efficiency, and delivers more meaningful therapeutic progress for patients worldwide.
December 15, 2025
 · 
9 min read
A contemporary artistic collage featuring a hand holding a trophy. The concept of victory and achievement.
Clinical research
5 of 2025’s Defining Clinical Wins
In the midst of regulatory and political upheaval, biopharma’s R&D engine kept running, churning out highs and lows in equal parts. Here are some of this year’s most glorious clinical trial victories.
December 15, 2025
 · 
9 min read
 · 
Tristan Manalac
RED pawn beating competition. 3D illustration. economic status and social achievement.3D rendering on black background.
Regulatory
FDA’s ‘Conundrum’: What To Do With Approved Drugs That Fail Pivotal or Confirmatory Trials
With notable therapies from Biogen, Sarepta and MacroGenics failing to show efficacy in pivotal or confirmatory trials, experts question the use of biomarker evidence for approval while one former regulator insists that a “failed trial is not a failed drug.”
December 15, 2025
 · 
7 min read
 · 
Heather McKenzie
A scientist with pill bottles in front of FDA headquarters
Regulatory
FDA Action Alert: GSK, Aldeyra, Rhythm and More
Coming up in the back half of December, the FDA will issue a verdict on Vanda Pharmaceuticals’ gastroparesis drug tradipitant, which it rejected last September, triggering a very public dispute with the company.
December 15, 2025
 · 
5 min read
 · 
Tristan Manalac
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS